INTRODUCTION
Conversations in High-Risk NMIBC is a roundtable discussion activity designed to present and discuss the latest clinical data in the treatment and management of NMIBC.
Launch Date: May 3, 2023
Release Date: May 3, 2023
Expiration Date: April 30, 2024
TARGET AUDIENCE
This activity is intended for clinicians who treat/manage patients with NMIBC. This includes community and institution based medical oncologists, urologists, and other oncology HCPs (nurse practitioners, physician assistants, nurses, and pharmacists).
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be able to:
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test ( accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is hour.
- Upon successful completion, your AMA/ANCC certificate will be emailed to you. ACPE credit will be submitted to Rush University Medical Center and posted to CPE Monitor.
ACCREDITATION STATEMENTS
PHYSICIANS
In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.
Rush University Medical Center designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is contact hours.
PHARMACISTS
Rush University Medical Center designates this knowledge-based CPE activity () for contact hours for pharmacists.
Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.
RESOLUTION OF CONFLICT OF INTEREST
It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.
DISCLOSURE
The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.
The following indicates the disclosure declaration information and the nature of those commercial relationships.
DISCLOSURES
The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
Jennifer Comerford
Nirupama Mulhekar
Louise King
Individuals in control of content for this activity have the following relevant financial relationships to disclose and all financial relationships have been mitigated.
FACULTY DISCLOSURES
Matthew Galsky, MD
Consulting: Alligator Bioscience, AstraZeneca, Bicycle Therapeutics, BMS, Curis, Dragonfly, Fujifilm, Genentech, Gilead, Janssen, Merck, NUMA, Pfizer, Rappta, Seagen, Urogen
Joshua Meeks, MD
Advisory Board: Astellas, AstraZeneca, BMS, Imvax, Incyte, Janssen, Merck, Pfizer, Prokarium, Seagen, Urogen
Abhishek Tripathi, MD
Research Grant: Aravive Inc, EMD Serono, WindMil Therapeutics
Consultant: EMD Serono, Exelixis, Seagen
DISCLAIMER
The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center and Practice Point Communications assume no liability for the information herein.
PRIVACY POLICY
The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by an independent educational grant from AstraZeneca.